ViGeneron GmbH
Dedicated to develop the medicines of the future
Dedicated to develop the medicines of the future
ViGeneron, founded in 2017 as a spin-off of the Ludwig-Maximilians-University (LMU) Munich, is dedicated to developing innovative gene therapies with a focus on addressing unmet medical needs. Leveraging two unique and proprietary technology platforms, the company aims to pioneer in-house gene therapy programs for selected retinal disorders, while also collaborating with partners to extend the application of its technologies to additional indications. The last significant investment for ViGeneron was a Series A investment on 29 November 2019, with backing from Sequoia China and WuXi AppTec. Headquartered in Germany, ViGeneron operates in the Biotechnology and Health Care industries, embodying a commitment to developing the medicines of the future.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | Unknown | 2 |
|
29 Nov 2019 |
No recent news or press coverage available for ViGeneron GmbH.
We care about your data, and we'd love to use cookies make your experience better.
